Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bortezomib”

920 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 920 results

Testing effectiveness (Phase 2)Study completedNCT02188537
What this trial is testing

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Who this might be right for
Myeloma
Swiss Cancer Institute 34
Early research (Phase 1)Ended earlyNCT00093704
What this trial is testing

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Who this might be right for
LymphomaLymphoproliferative Disorder
Jonsson Comprehensive Cancer Center 1
Large-scale testing (Phase 3)Ended earlyNCT02145598
What this trial is testing

Treatment Optimization in Patients With Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Dr. med. Lars-Olof Muegge 85
Not applicableActive Not RecruitingNCT05889221
What this trial is testing

Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

Who this might be right for
Multiple MyelomaMyeloma MultipleMyeloma
Poitiers University Hospital 74
Testing effectiveness (Phase 2)Study completedNCT00373906
What this trial is testing

Velcade in MALT Lymphoma Patients

Who this might be right for
MALT Lymphoma
Medical University of Vienna 16
Testing effectiveness (Phase 2)Ended earlyNCT04243109
What this trial is testing

Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

Who this might be right for
Multiple Myeloma
Maimónides Biomedical Research Institute of Córdoba 6
Large-scale testing (Phase 3)Active Not RecruitingNCT00644228
What this trial is testing

Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

Who this might be right for
DS Stage I Multiple MyelomaDS Stage II Multiple MyelomaDS Stage III Multiple Myeloma
National Cancer Institute (NCI) 525
Testing effectiveness (Phase 2)WithdrawnNCT01445587
What this trial is testing

GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

Who this might be right for
Cancer
GlaxoSmithKline
Not applicableStudy completedNCT01005628
What this trial is testing

Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)

Who this might be right for
Multiple Myeloma
Janssen Korea, Ltd., Korea 1,121
Early research (Phase 1)Study completedNCT00858234
What this trial is testing

Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

Who this might be right for
Multiple Myeloma
Merck Sharp & Dohme LLC 9
Testing effectiveness (Phase 2)Ended earlyNCT00265928
What this trial is testing

Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Virginia 46
Early research (Phase 1)Study completedNCT00903734
What this trial is testing

An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

Who this might be right for
Advanced Cancers
M.D. Anderson Cancer Center 16
Early research (Phase 1)Study completedNCT01164709
What this trial is testing

Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

Who this might be right for
LeukemiaLymphomaMature T-cell and Nk-cell Neoplasms+1 more
Swiss Cancer Institute 18
Large-scale testing (Phase 3)Active Not RecruitingNCT01208662
What this trial is testing

Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

Who this might be right for
Multiple Myeloma
Paul Richardson, MD 729
Not applicableStudy completedNCT00135187
What this trial is testing

Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

Who this might be right for
Multiple Myeloma
University of Michigan Rogel Cancer Center 30
Testing effectiveness (Phase 2)UnknownNCT04065308
What this trial is testing

Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

Who this might be right for
Multiple Myeloma in RelapsePlasmacytomaDaratumumab
Seoul National University Hospital 33
Early research (Phase 1)Study completedNCT00388089
What this trial is testing

Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors

Who this might be right for
Lung CancerUnspecified Adult Solid Tumor, Protocol Specific
University of California, Davis 24
Testing effectiveness (Phase 2)Study completedNCT00908232
What this trial is testing

Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

Who this might be right for
Multiple Myeloma
Janssen-Cilag International NV 163
Testing effectiveness (Phase 2)UnknownNCT00378755
What this trial is testing

Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

Who this might be right for
Multiple Myeloma
Korean Multiple Myeloma Working Party 62
Testing effectiveness (Phase 2)Study completedNCT00066352
What this trial is testing

Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
University Health Network, Toronto
Load More Results